Mouse Genome Informatics
cn
    Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2tm2Gth

involves: 129P2/OlaHsd
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• following adenoviral cre treatment, median survival time is 220 days

tumorigenesis
• following adenoviral cre treatment, 83% of mice develop highly invasive thoracic tumors (including malignant mesotheliomas, 45 of 57; rhabdomyosarcomas, 3 of 57; and schwannomas, 1 of 57)
• following adenoviral cre treatment, mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus
• following adenoviral cre treatment, 4% of mice develop aspecific tumors not induced by adeno-cre treatment
• following adenoviral cre treatment, 70% of mice develop aggressive malignant mesotheliomas, which is higher than in mice carrying other combinations of Cdkn2atm2Brn, Nf2tm2Gth, and Trp53tm1Brn alleles
• in 4% of mice following adenoviral cre treatment (J:132943)
• following adenoviral cre treatment, 7% mice develop monocytic myeloid leukemias

liver/biliary system
• following adenoviral cre treatment, 42% of mice develop hepatomegaly either due to oval cell hyperplasia, cholangio-carcinomas and/or hepatomas, and leiomyomas of the uterus

Mouse Models of Human Disease
OMIM IDRef(s)
Mesothelioma, Malignant; MESOM 156240 J:132943